The case for & against
Bull & Bear analysis
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a biotechnology company dedicated to developing innovative gene therapies for serious neurological diseases, particularly Alzheimer’s disease. The company focuses on optimizing delivery mechanisms across the central nervous system through its proprietary AAV (adeno-associated virus) capsid technology. Voyager's growing pipeline includes multiple programs targeting tau pathology, aiming to address significant unmet medical needs in treating neurodegenerative disorders. The potential markets for their therapies encompass biological systems that are currently in urgent need of effective treatment solutions.
Bull says
- ↑Cash reserves of $345M support trials through 2027.
- ↑Completed VY7523 enrollment; three IND filings due by 2026.
- ↑Proprietary AAV capsid tech enhances CNS delivery.
- ↑Partnerships with Novartis and Neurocrine bolster credibility.
- ↑High book-to-price ratio and moderate momentum signal value.
- ↑Hedge fund ownership rising; volatility offers trading opportunities.
Bear says
- ↓Q3 operating loss of $43M underscores rapid cash burn.
- ↓Earnings yield deeply negative; profitability remains elusive.
- ↓High leverage risk may strain balance sheet stability.
- ↓VY1706 trial missed primary endpoint in full population.
- ↓Analyst revisions trending downward amid size headwinds.
- ↓Negative profitability and leverage factors highlight financial strain.
Investment themes with VYGR
Genetic and drug innovations driving medical breakthroughs
Miscellaneous or uncategorized companies
Earnings Call · Q3 2022 · Mgmt. Guidance
Transcript signals
Bull points
- We've seen a pickup in volume and a pickup of our effectiveness of our marketing, again, in May. And, again, volume and volatility drive a lot and help us drive the cost down.
- we probably have the strongest crypto community in the industry. And we're leveraging that community to help drive the cost down.
- This morning, we announced that Voyager has obtained subscription agreements for a private placement and gross proceeds of approximately U.S. $60 million, led by Alameda Research, which was a follow-on investment from their strategic investment in October.
Bear points
- the activity that you're seeing from a trading perspective, are you seeing people actually putting money to work in crypto or are they liquidating positions and moving to cash or to stable cards?
- Voyager's discussions to date with the regulators demonstrate a willingness to work with Voyager to pursue a mutually acceptable regulatory framework.
- we expect to be break even to profitable in May and June. So a lot also from how profitable or, or break even if it's based upon the far row market as well.